Study Comparing Amrubicin Versus Topotecan in Patients With Small Cell Lung Cancer Who Have Responded to Prior Therapy.

NCT00319969 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

76

Enrollment

INDUSTRY

Sponsor class

Conditions

Small Cell Lung Cancer

Interventions

DRUG: Amrubicin
DRUG: Topotecan

Sponsor

Celgene Corporation